Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma.

J Transplant · 2014 · PMC4003738 · PMID 24818010

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significanceP value = 0.18not close (p > 0.1)

HCC Recurrence and Survival The mean follow-up for treated patients was longer than that for those in the historical group but this difference did not reach statistical significance (1125 versus 840 days, P value = 0.18).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.